DadFinStart your free week
DadFin › Stocks › Healthcare › PMN

ProMIS Neurosciences, Inc. (PMN) stock score

Healthcare · Biotechnology · Canada

$3.31 ▼ -70.13% today

15.8
Dad Score, out of 100
weak

ProMIS Neurosciences, Inc. (PMN) is a Biotechnology company in the Healthcare sector, listed in Canada. On DadFin's weekly run it scores 15.8 out of 100 on the Dad Score, a weak reading that places the business ahead of 16% of the 5,719 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #797 of 961. Its strongest axes are liquidity and macro; its weakest are valuation and quality.

Scores from the run of Oct 31, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Below average
Growth
Average
Price action
Weak
Risk
Below average
Conviction
Average
Liquidity
Strong
Macro
Strong

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)-0.7×
Dividend yield0.00%
Return on capital—
Operating margin0.0%
Revenue growth (YoY)+0.0%
FCF yield-119.3%
Net debt / EBITDA3.00×
Piotroski F-Score1 / 9
52-week change-67.7%
Market cap$30M
Next earnings—

What subscribers see on PMN

Start your free weekSubscriber? Open the full research →

Biotechnology peers

StockCompanyDad ScoreBandMarket cap
VRTXVertex Pharmaceuticals Incorporate94.8strong$141.6B
REGNRegeneron Pharmaceuticals, Inc.98.5strong$96.0B
MRNAModerna, Inc.32.5weak$88.5B
ARGXargenx SE96.5strong$56.1B
ONCBeOne Medicines AG99.9strong$42.1B
RVMDRevolution Medicines, Inc.23.7weak$41.0B
RPRXRoyalty Pharma plc96.3strong$38.8B
GMABGenmab A/S73.6good$35.1B

Prices from DadFin's live feed (refreshed about every 30 minutes in the session); scores from the weekly run of Oct 31, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.